[1] |
蔡明龙, 王文俊, 张学军. 银屑病全基因组关联分析与精准医学[J]. 中华皮肤科杂志, 2018,51(10):715⁃719. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.002.
|
[2] |
Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin⁃12 is increased in psoriatic skin[J]. J Invest Dermatol, 1998,111(6):1053⁃1057. doi: 10.1046/j.1523⁃1747.1998.00446.x.
|
[3] |
Ozawa A, Matsuo I, Niizuma K, et al. The major histocompatibility complex in psoriasis vulgaris. III. HLA⁃C antigens[J]. J Dermatol, 1979, 6(4):261⁃264. doi: 10.1111/j. 1346⁃8138.1979.tb01910.x.
|
[4] |
Zhang XJ, Huang W, Yang S, et al. Psoriasis genome⁃wide association study identifies susceptibility variants within LCE gene cluster at 1q21[J]. Nat Genet, 2009,41(2):205⁃210. doi: 10. 1038/ng.310.
|
[5] |
Eirís N, González⁃Lara L, Santos⁃Juanes J, et al. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus[J]. J Dermatol Sci, 2014,75(3):167⁃172. doi: 10.1016/j.jdermsci.2014. 05. 010.
|
[6] |
Sheng Y, Jin X, Xu J, et al. Sequencing⁃based approach identified three new susceptibility loci for psoriasis[J]. Nat Commun, 2014,5:4331. doi: 10.1038/ncomms5331.
|
[7] |
Yang Q, Liu H, Qu L, et al. Investigation of 20 non⁃HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris[J]. Br J Dermatol, 2013,168(5):1060⁃1065. doi: 10.1111/bjd. 12142.
|
[8] |
朱文元, 张学军, 张安平. 皖籍汉族人寻常型银屑病与HLA⁃Cw*0602等位基因的关联研究[J]. 临床皮肤科杂志, 2002,31(4):207⁃209. doi: 10.3969/j.issn.1000⁃4963.2002.04.002.
|
[9] |
黄艳平, 吕新翔, 孙志强, 等. 代谢综合征相关基因多态性与蒙古族寻常型银屑病的相关性及与HLA⁃C*06:02交互作用研究[J]. 中华皮肤科杂志, 2020,53(10):781⁃786. doi: 10. 35541/ cjd.20200505.
|
[10] |
Purcell S, Neale B, Todd⁃Brown K, et al. PLINK: a tool set for whole⁃genome association and population⁃based linkage analyses[J]. Am J Hum Genet, 2007,81(3):559⁃575. doi: 10.1086/519795.
|
[11] |
de Paus RA, van de Wetering D, van Dissel JT, et al. IL⁃23 and IL⁃12 responses in activated human T cells retrovirally transduced with IL⁃23 receptor variants[J]. Mol Immunol, 2008,45(15):3889⁃3895. doi: 10.1016/j.molimm.2008.06.029.
|
[12] |
Teng MW, Bowman EP, McElwee JJ, et al. IL⁃12 and IL⁃23 cytokines: from discovery to targeted therapies for immune⁃mediated inflammatory diseases[J]. Nat Med, 2015,21(7):719⁃729. doi: 10.1038/nm.3895.
|
[13] |
王刚. 银屑病免疫学研究新进展[J]. 中华皮肤科杂志, 2015,48(4):223⁃226. doi: 10.3760/cma.j.issn.0412⁃4030.2015.04.001.
|
[14] |
Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate⁃to⁃severe plaque psoriasis[J]. N Engl J Med, 2017, 376(16):1551⁃1560. doi: 10.1056/NEJMoa1607017.
|
[15] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019,52(12):863⁃871. doi: 10.35541/cjd.20190892.
|
[16] |
Loeff FC, Tsakok T, Dijk L, et al. Clinical impact of antibodies against ustekinumab in psoriasis: an observational, cross⁃sectional, multicenter study[J]. J Invest Dermatol, 2020,140(11):2129⁃2137. doi: 10.1016/j.jid.2020.03.957.
|
[17] |
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial[J]. Lancet, 2019,394(10201):831⁃839. doi: 10.1016/S0140⁃6736(19)31773⁃8.
|
[18] |
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials[J]. N Engl J Med, 2014,371(4):326⁃338. doi: 10.1056/NEJMoa1314258.
|